Bristol-Myers Squibb Company (BMY) Q3 2020 Earnings Results

Bristol Myers Squibb Beats on EPS, Stock Down 2.57%

Bristol Myers Squibb's earnings report showed a strong EPS performance, exceeding expectations. However, the stock declined by 2.57% following the announcement, likely due to the lack of revenue data and guidance. Investors may be concerned about the company's future growth potential without clearer direction.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$1.63	N/A	+9.62%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding their future prospects. They emphasized their commitment to innovation despite current market conditions.

Management highlighted the strength of their pipeline and ongoing research efforts.

They acknowledged challenges in the current market but expressed confidence in long-term growth.

Bristol Myers Squibb Beats on EPS, Stock Down 2.57%

Key numbers

Management commentary

Bristol-Myers Squibb Company

More earnings this week

Bristol Myers Squibb Beats on EPS, Stock Down 2.57%

Key numbers

Management commentary